IceCure Sees 70% Jump in U.S. Breast Cancer Cryoablation System Installations
ICCM is trading near its 52-week low of $2.12 (0.9% above the low) on elevated volume (1.9× avg).
Summary
IceCure Medical reported a substantial 70% increase in its active U.S. commercial install base for the ProSense® breast cancer cryoablation system. This significant growth follows FDA marketing authorization in October 2025 and is further bolstered by updated clinical guidelines from the American Society of Breast Surgeons recommending cryoablation. For a company that recently executed a 1-for-30 reverse stock split on June 4, 2026, and is trading near its 52-week low, this strong commercial adoption for a core product is a critical positive development, indicating increasing physician demand and potential for future revenue.
At the time of this announcement, ICCM was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $2.12 to $42.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.